Y-Mabs Therapeutics Inc (NASDAQ:YMAB) price on Thursday, July 03, rose 0.94% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $4.3.
A look at the stock’s price movement, the close in the last trading session was $4.26, moving within a range at $4.175 and $4.33. The beta value (5-Year monthly) was 0.506. Turning to its 52-week performance, $16.11 and $3.55 were the 52-week high and 52-week low respectively. Overall, YMAB moved -11.70% over the past month.
Y-Mabs Therapeutics Inc’s market cap currently stands at around $194.77 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-13.
Analysts have a consensus estimate of 18.4M for the company’s revenue for the quarter, with a low and high estimate of 18M and 19.3M respectively. The average forecast suggests down to a -19.31% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 82.41M, representing a -6.02% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that YMAB is a 25% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend YMAB as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
YMAB’s current price about -9.81% and -3.39% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 42.54, while 7-day volatility ratio is 5.24% and 7.71% in the 30-day chart. Further, Y-Mabs Therapeutics Inc (YMAB) has a beta value of 0.57. Analysts have given the company’s stock an average 52-week price target of $7, forecast between a low of $7 and high of $7. Looking at the price targets, the low is -62.79% off current price level while to achieve the yearly target high, price needs to move -62.79%. Nonetheless, investors will most likely welcome a -62.79% jump to $7 which is the analysts’ median price.
If we refocus on Y-Mabs Therapeutics Inc (NASDAQ:YMAB), historical trading data shows that trading volumes averaged 0.25 over the past 10 days and 229.25K over the past 3 months. The company’s latest data on shares outstanding shows there are 45.25 million shares.
The 24.88% of Y-Mabs Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 59.03% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.65 million on 2025-06-13, giving us a short ratio of 12.94. The data shows that as of 2025-06-13 short interest in Y-Mabs Therapeutics Inc (YMAB) stood at 694.0 of shares outstanding, with shares short falling to 2.84 million registered in 2025-05-15. Current price change has pushed the stock -63.65% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the YMAB stock continues to rise going into the next quarter.
